Anamorelin

Drug Profile

Anamorelin

Alternative Names: Adlumiz; Anamorelin HCl; Anamorelin hydrochloride; ONO-7643; RC-1291; ST-1291

Latest Information Update: 10 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novo Nordisk
  • Developer Helsinn Therapeutics; Ono Pharmaceutical
  • Class Appetite stimulants; Piperidines; Small molecules
  • Mechanism of Action Ghrelin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Anorexia; Cachexia
  • Phase II Fatigue

Most Recent Events

  • 23 Jun 2017 Hensinn Birex Pharmaceuticals requests for re-examination of the CHMP negative opinion for anamorelin
  • 19 May 2017 CHMP adopts negative opinion for approval of anamorelin for Anorexia and Cachexia in European Union
  • 17 May 2017 Efficacy data from a pooled analysis of the phase III ROMANA 1 and 2 trials in Cachexia (in NSCLC patients) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top